Compare liraglutide prices across GPhC-registered UK pharmacies. Sold as Saxenda by some providers and Nevolat by others — both contain liraglutide, the same active ingredient. Verified weekly. No pharmacy pays to rank first.
GPhC-verified only No paid placements Updated April 2026
Saxenda and Nevolat share the same active ingredient. Both contain liraglutide 6mg/ml and are injected daily using the same pen device. Saxenda and Nevolat are brand names for liraglutide sold by different pharmacies. The active ingredient, dosing schedule and clinical effects are identical.
Prices by pack size
Verified April 2026
Each pen contains 3ml of liraglutide 6mg/ml. Treatment starts at 0.6mg daily and titrates up to 3mg over 5 weeks.
Type:
Sort:
Pharmacy
Price / month
Trustpilot
Verified
Seen a cheaper price somewhere?
Spotted a lower price?
We verify all submissions and update our listings weekly. Your tip helps other patients save money.
Important: Private prescription only. Saxenda is a prescription-only medicine — a clinical assessment is required before any pharmacy can supply it. Always verify pharmacy registration at pharmacyregulation.org.
About Saxenda
How it works
Saxenda contains liraglutide, a GLP-1 receptor agonist that mimics the natural gut hormone GLP-1, which is released after eating. It acts on the brain to reduce appetite and slow the rate at which food leaves the stomach, helping patients feel full more quickly and for longer. Unlike Mounjaro and Wegovy, which are injected once a week, Saxenda is injected once daily. The daily dosing means it leaves the body more quickly, which some patients find easier to manage if side effects occur.
Saxenda is an older drug in this class — approved by the MHRA for weight management in 2015 — and has been available on the NHS since 2020. Clinical trial results are more modest than the newer weekly injections, but for some patients it remains the right choice: particularly those who prefer daily control, who have not tolerated weekly GLP-1 medications, or where Wegovy or Mounjaro are not accessible locally.
Clinical trial results
The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) trial programme provided the evidence base for Saxenda's licence. In the SCALE Obesity and Prediabetes trial, patients on the 3mg maintenance dose lost an average of 8.4% of body weight over 56 weeks, compared to 2.8% with placebo. Around 63% of patients on liraglutide achieved at least 5% weight loss, and 33% achieved at least 10%.
These figures are lower than those seen with Wegovy (15–17% at 68 weeks) and Mounjaro (~20% at 72 weeks). However, Saxenda has a longer established safety record, and for some patient groups — particularly those with a history of poor tolerability of weekly injections — it may be more appropriate.
Doses and dosing schedule
Treatment starts at 0.6mg daily for one week, then increases by 0.6mg each week until reaching the 3mg maintenance dose — a five-week process. The dose is increased gradually to reduce the likelihood of gastrointestinal side effects. Each pen contains enough medication for approximately two weeks at the maintenance dose. Unlike Mounjaro and Wegovy, Saxenda does not come with needles included in the pen — these must be ordered separately.
Who is it for?
Private prescription
BMI ≥ 30, or BMI ≥ 27 with a weight-related condition
Adults aged 18 and over
Not pregnant or planning pregnancy
No personal or family history of medullary thyroid cancer or MEN2
Who should not take Saxenda: people who are pregnant or planning to become pregnant, those breastfeeding, and anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is also not suitable for patients with a prior history of pancreatitis or severe gastrointestinal disease.
Needles not included: unlike Mounjaro and Wegovy, NHS guidance confirms that Saxenda pens do not include needles. You will need to order compatible needles separately — check with your pharmacy what is included in the price before purchasing.
Side effects
Side effects are similar to those seen with other GLP-1 medications and are most common at the start of treatment or after a dose increase. The weekly dose increases are designed to reduce their severity.
Nausea
Very common in the first weeks. Usually improves as the body adjusts to treatment.
Diarrhoea / constipation
Common. Staying well hydrated and eating smaller meals helps manage symptoms.
Vomiting
Common at dose increases. Eating slowly and avoiding large or fatty meals helps.
Abdominal pain
Mild stomach discomfort is common, particularly early in treatment.
Injection site reactions
Mild redness or discomfort at the injection site. Rotating sites daily reduces frequency.
Pancreatitis (rare)
Severe abdominal pain with or without vomiting — seek immediate medical help.
Saxenda produces less average weight loss than the newer weekly injections — around 8% at 56 weeks, compared to 15–17% for Wegovy and ~20% for Mounjaro. It is also a daily rather than weekly injection and tends to be more expensive per month at the maintenance dose. However, Saxenda may suit patients who prefer daily dosing control (since its shorter duration means it leaves the body faster if you need to stop), who have not tolerated weekly GLP-1 medications, or where the newer drugs are not available locally on the NHS. It also has the longest established safety record of the three.
Saxenda is available on the NHS in England under NICE guidance TA664, but only through specialist tier 3 weight management services — not from a GP directly. You need a BMI of 35 or above with at least one weight-related comorbidity. Crucially, NHS availability varies considerably between areas: many Integrated Care Boards have restricted or declined to commission Saxenda, particularly now that Mounjaro and Wegovy are also available. Your GP can refer you for a tier 3 assessment, but there may be a waiting list or the drug may not be available in your area. Treatment is funded for a maximum of two years.
Saxenda uses liraglutide, which has a shorter half-life than semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro). This means it is cleared from the body more quickly — within roughly 24 hours — which is why a daily injection is needed to maintain its effect. Some patients see this as an advantage: if you experience side effects, stopping the daily injection means the drug clears your system within a day or two, whereas stopping a weekly injection means effects may persist for several days. For others, the daily injection schedule is harder to maintain long-term.
No. Unlike Mounjaro and Wegovy, Saxenda pens do not include needles. You will need to purchase compatible pen needles separately. Ask your pharmacy what is and is not included in the quoted price before buying — some online pharmacies include needles in their package, others do not. Standard 4mm or 8mm pen needles (32 gauge) are compatible with the Saxenda pen.
Most patients notice reduced appetite within the first few weeks of reaching a meaningful dose. The full five-week increase from 0.6mg to the 3mg maintenance dose takes approximately five weeks. Visible weight loss typically becomes apparent from around weeks 4–8. Clinical trials measured results at 56 weeks (about 13 months).
As with other GLP-1 medications, most patients regain weight after stopping Saxenda once the appetite-suppressing effect is removed. Because liraglutide clears the body faster than weekly GLP-1 drugs, the effect on appetite diminishes within a day or two of stopping. Real-world data from NHS tier 3 services show that weight regain typically begins shortly after the drug is discontinued, which is why sustained lifestyle changes during treatment are important.
Available under NICE TA664 through specialist tier 3 services only. Maximum 2 years. Availability varies significantly — many areas have restricted or not commissioned it. Full NHS eligibility guide →